GSK highlights pipeline products
GSK also highlighted its drugs expected to see filings and/or approvals in 2005 include:
*Entereg to accelerate gastrointestinal recovery following abdominal surgery. The FDA has accepted an NDA for Entereg. The FDA action date is April 25, 2005.
*Trexima for migraine. Trexima is expected to provide superior efficacy when combined with naproxen sodium. Filing is expected in the first half of 2005.
*Requp/Adartrel for the treatment of restless leg syndrome, the third most common cause of sleep disturbance. GSK expects to gain U.S. approval for Requp/Adartrel for the treatment of RLS in the first half of 2005.
GSK has 148 projects in clinical development, including 90 new chemical entities (NCEs) - an 80 percent increase since the merger of Glaxo Wellcome and Smithkline Beecham.
A complete listing of all compounds in the GSK research pipeline is available at www.gsk.com.